Class / Patent application number | Description | Number of patent applications / Date published |
514619000 | Nitrogen in R | 70 |
20080200551 | Flourene Derivative - This invention relates to a novel fluorene derivative having a characteristic structure in which guanidino group or the like functional group is linked to the fluorene structure via carbonyl group, or a salt thereof. | 08-21-2008 |
20090012177 | Treatment of psychiatric disorders using entacapone, tolcapone and other COMT inhibitor or MB-COMT inhibitor drugs - The invention provides a method for the treatment of certain psychiatric disorders using entacapone, tolcapone and other COMT inhibitor drugs or MB-COMT inhibitor compounds. The method is effective in particular for improving positive and negative symptoms of Schizophrenia (SCZ), major depression, the depressive phase of Bipolar Disorder (BD) and substance dependency. The method can also be used as a treatment to combat cravings associated with abuse of alcohol, opiates, cocaine, marijuana, amphetamines and Tobacco addiction. In addition to these diseases it is useful for the treatment of ADD/ADHD, cognitive enhancement in head injuries and dementias. | 01-08-2009 |
20090018203 | MODIFIED RELEASE COMPOSITIONS OF MILNACIPRAN - A milnacipran formulation that provides delayed and extended release of milnacipran has been developed. The formulation comprises milnacipran or a salt thereof; an extended release excipient, and a delayed release excipient. The formulation provides, upon administration to a human subject, a T | 01-15-2009 |
20090054525 | SELECTIVE ANDROGEN RECEPTOR MODULATORS - A compound of formula (I), an isomer, metabolite, or a pharmaceutically acceptable salt or ester thereof is disclosed. Compounds of the invention possess utility as a tissue-selective androgen receptor modulators (SARM) and are useful in hormonal therapy, e.g. in the treatment or prevention of hypogonadism, muscle wasting, osteoporosis, benign prostate hyperplasia, obesity associated with a metabolic syndrome, male and female sexual dysfunction and reduced libido, and androgen decline in aging male or female. | 02-26-2009 |
20090131529 | TREATMENT OF BREAST CANCER WITH A PARP INHIBITOR ALONE OR IN COMBINATION WITH ANTI-TUMOR AGENTS - In one aspect, the present invention provides a method of treating breast cancer that is negative for at least one of ER, PR, or HER2, comprising administering to a subject at least one PARP inhibitor. In another aspect, the present invention provides a method of treating breast cancer comprising administering to a subject at least one PARP inhibitor in combination with at least one anti-tumor agent. | 05-21-2009 |
20090131530 | 4- (OR 5-) SUBSTITUTED CATECHOL DERIVATIVES - Compounds of the formula: | 05-21-2009 |
20090264534 | SELECTIVE ANDROGEN RECEPTOR MODULATORS - The present invention relates to androgen receptor targeting agents (ARTA) which demonstrate androgenic and anabolic activity, which are nonsteroidal ligands for the androgen receptor. The selective androgen receptor modulators (SARM) are useful for a) male contraception; b) treatment of a variety of hormone-related conditions, for example conditions associated with Androgen Decline in Aging Male (ADAM), such as fatigue, depression, decreased libido, sexual dysfunction, erectile dysfunction, hypogonadism, osteoporosis, hair loss, anemia, obesity, sarcopenia, osteopenia, osteoporosis, benign prostate hyperplasia, alterations in mood and cognition and prostate cancer; c) treatment of conditions associated with Androgen Decline in Female (ADIF), such as sexual dysfunction, decreased sexual libido, hypogonadism, sarcopenia, osteopenia, osteoporosis, alterations in cognition and mood, depression, anemia, hair loss, obesity, endometriosis, breast cancer, uterine cancer and ovarian cancer; d) treatment and/or prevention of chronic muscular wasting; e) decreasing the incidence of, halting or causing a regression of prostate cancer; f) oral androgen replacement and/or other clinical therapeutic and/or diagnostic areas. | 10-22-2009 |
20090312429 | Administration of nepafenac or derivatives thereof for treating dermatological/keratinization disorders - Nepafenac or derivatives thereof are useful for the treatment of dermatological conditions related to a keratinization disorder that may have an inflammatory immunoallergic component, for example rosacea, acne, psoriasis or atopic dermatitis. | 12-17-2009 |
20100010094 | Novel nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents - The present invention relates to novel nitrophenyl mustard and nitrophenylaziridine alcohols, to their corresponding phosphates, to their use as targeted cytotoxic agents; as bioreductive drugs in hypoxic tumours, and to their use in cell ablation, including gene-directed enzyme-prodrug therapy (GDEPT) and antibody-directed enzyme-prodrug therapy (ADEPT), in conjunction with nitroreductase enzymes. | 01-14-2010 |
20100016439 | OPHTHALMIC DEVICE HAVING THERAPEUTIC AGENT DELIVERY CAPABILITY AND METHOD OF FORMING SAME - The present invention is directed to ophthalmic devices that are loaded with therapeutic agent. The devices provide prolonged release of the therapeutic agent to the eye. The ophthalmic devices are typically formed of an ophthalmic material that is particularly desirable for the loading of therapeutic agent and/or the therapeutic agent is typically particularly desirable for loading to the ophthalmic material. | 01-21-2010 |
20100056638 | Oral and Injectable Formulations of Tetracycline Compounds - Injectable and oral formulations of a tetracycline compound are described. In one embodiment, the invention pertains to an oral formulation of a 9-aminomethyl tetracycline compound, or a salt thereof, in tablet form or capsule. The formulations may be used, for example, to treat infections. | 03-04-2010 |
20100056639 | INSECTICIDAL COMPOUNDS - A compound of formula (I): wherein A | 03-04-2010 |
20100113602 | USE OF HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM METASTASES - Disclosed is a method of treating a localized carcinoma central nervous system (CNS) metastasis of extra-CNS origin, the method comprising systemically administering an effective amount of a histone deacetylase (HDAC) inhibitor (HDI) to a subject in need of treatment for the localized carcinoma CNS metastasis of extra-CNS origin. The HDI can be any HDI capable of crossing the blood-brain barrier (BBB) such as vorinostat. The localized carcinoma CNS metastasis of extra-CNS origin can be a localized carcinoma brain metastasis. The localized carcinoma brain metastasis can originate in the breast. The CNS metastasis treated can be a micrometastasis, a brain tumor, or an intervening stage of brain cancer. | 05-06-2010 |
20100144885 | HISTONE ACETYL TRANSFERASE ACTIVATORS AND HISTONE DEACETYLASE INHIBITORS IN THE TREATMENT OF ALCOHOLISM - The present invention relates to the reduction of a symptom of an alcohol withdrawal state comprising administering a modulator of histone acetylation. | 06-10-2010 |
20100160442 | FORMULATIONS FOR CANCER TREATMENT - The present invention provides compositions of matter, kits, and methods for use in treating cancer and viral conditions. In particular the invention provides for pharmaceutical compositions containing nitrobenzamide compounds that have enhanced solubility in aqueous solutions. | 06-24-2010 |
20100197795 | TRANSDERMAL COMPOSITIONS - The present invention is directed to transdermal compositions and the uses thereof. These compositions include at least one of the following components: a C | 08-05-2010 |
20100234469 | New Crystals Of A Benzoylbenzeneacetamide Derivative - The invention relates to 2-amino-3-benzoylbenzeneacetamide, i.e. nepafenac, crystals having reduced chargeability, to processes for the preparation thereof, and to the use thereof for preparing pharmaceutical formulations. | 09-16-2010 |
20110015271 | TOPICAL NEPAFENAC FORMULATIONS - Topical suspension compositions of nepafenac are disclosed. The compositions are especially suitable for topical ophthalmic administration. | 01-20-2011 |
20110207823 | 12-HOUR SUSTAINED-RELEASE METOCLOPRAMIDE - The present invention consists of an extended-release metoclopramide hydrochloride pharmaceutical composition, in 15 mg drug substance tablets, for use in gastrointestinal disorders. The formulation is mainly composed of a hydrophilic polymer, a hydrophobic polymer, a hydrophilic component and metoclopramide hydrochloride. The hydrophilic polymer is swollen by hydration when contacting water, forming a gel coat which controls drug substance release. The water inside the matrix dissolves the drug substance and this is diffused outside through the gel coat. The hydrophobic polymer shows plastic deformation properties under compression, tending to surround the drug substance particles reducing the pore quantity and dimensions in the matrix structure, delaying as a consequence the drug substance release. The hydrophilic component is part of the gel coating structure providing support thereto. Drug substance is the metoclopramide hydrochloride or a pharmaceutically acceptable salt thereof. | 08-25-2011 |
20110301242 | Inhibitors of Cathepsin S for Prevention or Treatment of Obesity-Associated Disorders - The present invention relates to methods (and pharmaceutical compositions) for treating and/or preventing for obesity associated disorders, particularly related to a deregulation of glucose homeostasis, by administrating Cathepsin S inhibitors. The invention also relates to methods for diagnosing insulin resistance and glucose tolerance by measuring Cathepsin S levels in a biological sample obtained from a subject. | 12-08-2011 |
20120029084 | Topical Nepafenac Formulations - Topical suspension compositions of nepafenac are disclosed. The compositions are especially suitable for topical ophthalmic administration. | 02-02-2012 |
20120157539 | NUCLEAR RECEPTOR BINDING AGENTS - The present invention relates to a novel class of selective estrogen receptor modulators (SERMs). The SERM compounds are applicable for use in the prevention and/or treatment of a variety of diseases and conditions including prevention and treatment of cancers such as prostate and breast cancer, osteoporosis, hormone-related diseases, hot flashes or vasomotor symptoms, neurological disorders, cardiovascular disease and obesity. | 06-21-2012 |
20130090386 | LYSINE SPECIFIC DEMETHYLASE-1 INHIBITORS AND THEIR USE - The present invention relates to a compound of Formula 1, wherein: (A) is heteroaryl or aryl; each (A′), if present, is independently chosen from aryl, arylalkoxy, arylalkyl, heterocyclyl, aryloxy, halo, alkoxy, haloalkyl, cycloalkyl, haloalkoxy, and cyano, wherein each (A′) is substituted with 0, 1, 2, or 3 substituents independently chosen from halo, haloalkyl, haloalkoxy, aryl, arylalkoxy, alkyl, alkoxy, amido, —CH | 04-11-2013 |
20130217775 | TREATMENT OF SYMPTOMS ASSOCIATED WITH FEMALE GASTROPARESIS - Nasal formulations of metoclopramide are administered for the treatment of symptoms associated with female gastroparesis. Also provided are methods of treating symptoms of female gastroparesis with nasal metoclopramide. | 08-22-2013 |
20130231393 | USE OF SQUARAMIDE IN THE PREVENTION AND/OR TREATMENT OF ROSACEA - A compound of formula (I): | 09-05-2013 |
20130331457 | TREATMENT OF CANCER - Methods of treating bladder cancer are disclosed. The methods include administering to a patient a therapeutically effective amount of a 4-iodo-3-nitrobenzamide or a pharmaceutically acceptable salt thereof. | 12-12-2013 |
20140163111 | POROUS BIOMOLECULE-CONTAINING METAL-ORGANIC FRAMEWORKS - The invention relates to compositions including porous biomolecule-containing metal-organic frameworks and methods for their preparation. The porous biomolecule-containing metal-organic frameworks can include a metal component and a biomolecule component. The pores located within the frameworks have a pore space and said pore space is capable to adsorb materials therein. These compositions of the invention are useful in a wide variety of applications, such as, but not limited to, hydrogen and carbon dioxide sequestration, separation and storage; carbon dioxide uptake; and drug storage and release. | 06-12-2014 |
20140179794 | LEVOMILNACIPRAN-BASED DRUG FOR FUNCTIONAL RECOVERY AFTER ACUTE NEUROLOGICAL EVENTS - The present invention concerns the use of levomilnacipran as medicinal product in functional recovery after a cerebrovascular accident or traumatic brain injury. The pharmaceutical compositions containing levomilnacipran are exclusively those not containing dextromilnacipran to a proportion of more than 5% by weight of the levomilnacipran/dextromilnacipran mixture, to avoid compromising functional recovery due to the alpha1-blocking property of dextromilnacipran. | 06-26-2014 |
20140213657 | LYSINE SPECIFIC DEMETHYLASE-1 INHIBITORS AND THEIR USE - The present invention relates to a compound of Formula 1, wherein: (A) is heteroaryl or aryl; each (A′), if present, is independently chosen from aryl, arylalkoxy, arylalkyl, heterocyclyl, aryloxy, halo, alkoxy, haloalkyl, cycloalkyl, haloalkoxy, and cyano, wherein each (A′) is substituted with 0, 1, 2, or 3 substituents independently chosen from halo, haloalkyl, haloalkoxy, aryl, arylalkoxy, alkyl, alkoxy, amido, —CH | 07-31-2014 |
20140316008 | N-PHENYL ANTHRANILIC ACID DERIVATIVES AND USES THEREOF - Compounds that can be used as openers or blockers of voltage-dependent potassium channels, and which are useful in the treatment of conditions such as central or peripheral nervous system disorders through the modulation of potassium ion flux through voltage-dependent potassium channels and/or depressing or enhancing cortical and/or peripheral neuron activity, compositions containing same and methods utilizing same are disclosed. Also disclosed are modulators of voltage-dependent potassium channels, which exhibit blocking of a TRPV1 channel, and hence are useful in the treatment of TRPV1-related conditions. | 10-23-2014 |
20150087711 | MINOCYCLINE COMPOUNDS AND METHODS OF USE THEREOF - Methods and compositions for using a tetracycline compound to treat bacterial infections are described. In one embodiment, for example, the invention provides a method of treating a subject for an infection, comprising administering to said subject an effective amount of 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof, such that said subject is treated, wherein said infection is selected from the group consisting of MSSA, MRSA, | 03-26-2015 |
20150291510 | INSECTICIDAL COMPOUNDS - The present invention relates to novel triazole derivatives of formula (I) having insecticidal activity, to processes and intermediates for preparing them, to insecticidal, acaricidal, nematicidal or molluscicidal compositions comprising them and to methods of using them to combat and control insect, acarine, nematode or mollusc pests; wherein R | 10-15-2015 |
20150315132 | AMINOCYCLOBUTANE DERIVATIVES, METHOD FOR PREPARING SAME AND THE USE THEREOF AS DRUGS - The present inventions concerns derivatives of aminocyclobutane, particularly as NMDA receptor antagonists, their application in human therapy and their method of preparation. | 11-05-2015 |
20150368186 | LYSINE SPECIFIC DEMETHYLASE-1 INHIBITORS AND THEIR USE - The present invention relates to a compound of Formula 1, wherein: (A) is heteroaryl or aryl; each (A′), if present, is independently chosen from aryl, arylalkoxy, arylalkyl, heterocyclyl, aryloxy, halo, alkoxy, haloalkyl, cycloalkyl, haloalkoxy, and cyano, wherein each (A′) is substituted with 0, 1, 2, or 3 substituents independently chosen from halo, haloalkyl, haloalkoxy, aryl, arylalkoxy, alkyl, alkoxy, amido, —CH | 12-24-2015 |
20190144375 | NOVEL CARBOCYCLIC COMPOUNDS AS ROR GAMMA MODULATORS | 05-16-2019 |
514620000 | The nitrogen in R is an amino nitrogen attached indirectly to a ring by acyclic bonding | 35 |
20080221217 | Phenyl Compounds and Their Use in the Treatment of Type II Diabetes - The present invention is directed to compounds of formula (I) or a pharmaceutically acceptable salt thereof; wherein A is (xx); X is selected from CH, CF and N, R5 is selected from H, C | 09-11-2008 |
20080293819 | DI-FLUORO CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS - The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S, and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them. | 11-27-2008 |
20080293820 | METHODS FOR IMPROVING PHYSICAL FUNCTION IN FIBROMYALGIA - Methods for improving physical function in fibromyalgia syndrome by administering an NSRI such as milnacipran as disclosed. | 11-27-2008 |
20080312330 | Methods for Reducing Mortality and Morbidity by Postoperative Administration of a Pharmacologic Cardiovascular Agent - The present invention relates to methods for reducing mortality and cardiovascular morbidity following surgery. In particular, the invention relates to the intensive postoperative administration of a pharmacologic cardiovascular agent to reduce mortality and cardiovascular complications. The invention is illustrated by way of working examples which demonstrate that in patients with, or at risk for, coronary artery disease undergoing major noncardiac surgery, the administration of a 3-adrenergic blocking agent throughout the period of hospitalization: 1) reduces mortality and cardiovascular events following hospital discharge; 2) is safe and well tolerated; and 3) the estimated cost savings in lives more than outweighs the cost of therapy. | 12-18-2008 |
20080319083 | MEDICINE FOR TRANSNASAL ADMINISTRATION - The object is to provide an SNRI-containing preparation which has a higher absorbability compared to a conventional SNRI preparation, produces its effect rapidly, and is readily administered to a patient who is hard to be administered via an oral route. | 12-25-2008 |
20090069431 | DEUTERIUM-ENRICHED MILNACIPRAN - The present application describes deuterium-enriched milnacipran, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 03-12-2009 |
20090088480 | SOLID FORMS OF SELECTIVE ANDROGEN RECEPTOR MODULATORS - The present invention relates to solid forms of (S)—N-(4-cyano-3-(trifluoromethyl)phenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide and process for producing the same. | 04-02-2009 |
20090149544 | Alpha-aminoamide derivatives - This invention relates to novel alpha-aminoamide derivatives, their pharmaceutically acceptable salts, solvates, and hydrates thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering an inhibitor of monoamine oxidase type B (MAO-B) and/or a sodium (Na | 06-11-2009 |
20100016440 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL AS ANTI-INFLAMMATORY AGENTS - Methods of using certain a-aminoamide derivatives as anti-inflammatory agents. The anti-inflammatory agents of the invention are able to reduce or even stop inflammatory s conditions substantially without side effects. | 01-21-2010 |
20100081719 | MILNACIPRAN FOR THE TREATMENT OF FATIGUE ASSOCIATED WITH FIBROMYALGIA SYNDROME - Methods for treating fatigue associated with fibromyalgia by administering high-dose milnacipran to a patient suffering from such fatigue are provided. Also provided are methods for the long-term treatment of fatigue associated with FMS by administering milnacipran to a patient suffering from such fatigue. | 04-01-2010 |
20100105778 | METHODS OF TREATING FIBROMYALGIA SYNDROME, CHRONIC FATIGUE SYNDROME AND PAIN - The present invention provides a method of treating fibromyalgia syndrome (FMS), chronic fatigue syndrome (CFS), and pain in an animal subject. The method generally involves administering a therapeutically effective amount of a dual serotonin norepinephrine reuptake inhibitor compound or a pharmaceutically acceptable salt thereof, wherein said dual serotonin norepinephrine reuptake inhibitor compound is characterized by a non-tricyclic structure and an equal or greater inhibition of norepinephrine reuptake than serotonin reuptake. In particular, the use of milnacipran to treat FMS, CFS, and pain is disclosed. | 04-29-2010 |
20100105779 | METHODS OF TREATING FIBROMYALGIA SYNDROME, CHRONIC FATIGUE SYNDROME AND PAIN - The present invention provides a method of treating fibromyalgia syndrome (FMS), chronic fatigue syndrome (CFS), and pain in an animal subject. The method generally involves administering a therapeutically effective amount of a dual serotonin norepinephrine reuptake inhibitor compound or a pharmaceutically acceptable salt thereof, wherein said dual serotonin norepinephrine reuptake inhibitor compound is characterized by a non-tricyclic structure and an equal or greater inhibition of norepinephrine reuptake than serotonin reuptake. In particular, the use of milnacipran to treat FMS, CFS, and pain is disclosed. | 04-29-2010 |
20100120921 | RENIN INHIBITORS FOR TREATMENT OF HYPERTENSION IN PATIENTS WITH HIGH SODIUM DIET - The present invention relates to methods for the prevention of, delay of progression to, or treatment of hypertension in a patient with a high sodium diet, comprising administering to such a patient a therapeutically effective amount of a renin inhibitor or a pharmaceutically acceptable salt thereof. | 05-13-2010 |
20100168243 | Renin Inhibitors - The present invention is directed to aspartic protease inhibitors. The present invention is also directed to pharmaceutical compositions comprising the disclosed aspartic protease inhibitors. The present invention is further directed to methods of antagonizing one or more aspartic proteases in a subject in need thereof, and methods for treating an aspartic protease mediated disorder in a subject using the disclosed aspartic protease inhibitors. | 07-01-2010 |
20100197796 | METHODS OF TREATING FIBROMYALGIA SYNDROME, CHRONIC FATIGUE SYNDROME AND PAIN - The present invention provides a method of treating fibromyalgia syndrome (FMS), chronic fatigue syndrome (CFS), and pain in an animal subject. The method generally involves administering a therapeutically effective amount of a dual serotonin norepinephrine reuptake inhibitor compound or a pharmaceutically acceptable salt thereof, wherein said dual serotonin norepinephrine reuptake inhibitor compound is characterized by a non-tricyclic structure and an equal or greater inhibition of norepinephrine reuptake than serotonin reuptake. In particular, the use of milnacipran to treat FMS, CFS, and pain is disclosed. | 08-05-2010 |
20100197797 | METHODS OF MANAGING FIBROMYALGIA USING MILNACIPRAN - The present invention relates to compositions comprising milnacipran or a pharmaceutically acceptable salt thereof (e.g., milnacipran hydrochloride) and methods for managing fibromyalgia comprising administering milnacipran or a pharmaceutically acceptable salt thereof (e.g., milnacipran hydrochloride). The present invention also relates to titration packs comprising dosage forms (e.g., tablets) comprising milnacipran or a pharmaceutically acceptable salt thereof (e.g., milnacipran hydrochloride) for oral administration. The titration packs enable patient compliance with a regime of changing dosage of the milnacipran or pharmaceutically acceptable salt thereof (e.g., milnacipran hydrochloride). | 08-05-2010 |
20110065800 | FORMULATIONS FOR CATHEPSIN K INHIBITORS - The instant invention relates to pharmaceutical compositions containing cathepsin K inhibitors. Also disclosed are processes for making said pharmaceutical compositions. | 03-17-2011 |
20110112197 | NOVEL CRYSTALLINE FORMS OF (1S,2R)-2-(AMINO METHYL)-N,N-DIETHYL-1-PHENYL CYCLOPROPANE CARBOXAMIDE - The present invention relates to novel crystalline forms of (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide. Processes for the preparation of this form, compositions containing the form, and methods of use thereof are also described. | 05-12-2011 |
20110118356 | INSECTICIDAL COMPOUNDS - A compound of formula (I) wherein A | 05-19-2011 |
20110144210 | STABLE DOSAGE FORMS OF LEVOMILNACIPRAN - The present invention relates to stable dosage forms of levomilnacipran and pharmaceutically acceptable salts thereof. Processes for the preparation of these dosage forms and methods of using these dosage forms are also described. | 06-16-2011 |
20110160308 | Use of Monoamine Oxidase Inhibitors to Treat Outer Retina Disorders - Compositions and methods for treating disorders of the outer retina with compounds that inhibit monoamine oxidase are disclosed. | 06-30-2011 |
20110172310 | DI-FLUORO CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS - The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S, and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them. | 07-14-2011 |
20120010296 | TREATING VARIOUS DISORDERS WITH CATECHOL-O-METHYL-TRANSFERASE INHIBITORS - The invention provides methods for treating disorders in patients with catechol-o-methyl-transferase inhibitors, such as impulse control disorders and cognitive disorders, such as attention deficit hyperactivity disorder. The invention also provides methods for treating patients with obsessive compulsive disorders and substance addictions with catechol-o-methyl-transferase inhibitors. | 01-12-2012 |
20120295982 | TREATING HUMAN MALE COPD PATIENTS WITH ORAL BEDORADRINE - A method of treating a human male patient is disclosed. Enterally administering bedoradrine or a pharmaceutically acceptable salt thereof to a human male patient who is suffering from a medical condition that is responsive to bedoradrine or a pharmaceutically acceptable salt thereof, is useful and benefits human males versus human females. A preferred mode of administration is oral administration. | 11-22-2012 |
20130072564 | PEPTIDE AND SMALL MOLECULE AGONISTS OF EPHA AND THEIR USES - Methods and compositions for activating an EphA receptor can be used for identifying therapeutic agents for cancer. | 03-21-2013 |
20130210919 | NOVEL CRYSTALLINE FORMS OF (1S,2R)-2-(AMINO METHYL)-N,N-DIETHYL-1-PHENYL CYCLOPROPANE CARBOXAMIDE - The present invention relates to novel crystalline forms of (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide. Processes for the preparation of this form, compositions containing the form, and methods of use thereof are also described. | 08-15-2013 |
20130253063 | STABLE DOSAGE FORMS OF LEVOMILNACIPRAN - The present invention relates to stable dosage forms of levomilnacipran and pharmaceutically acceptable salts thereof. Processes for the preparation of these dosage forms and methods of using these dosage forms are also described. | 09-26-2013 |
20130317110 | COMPOUND, KINESIN SPINDLE PROTEIN INHIBITOR, AND APPLICATION THEREOF - A compound represented by the following General Formula (I): | 11-28-2013 |
20140018433 | METHOD OF TREATING ANDROGEN RECEPTOR (AR) -POSITIVE BREAST CANCERS WITH SELECTIVE ANDROGEN RECEPTOR MODULATOR (SARMS) - This invention relates to the treatment of androgen receptor-positive breast cancer in a subject, for example a female subject. Accordingly, this invention provides methods of: a) treating a subject suffering from breast cancer; b) treating a subject suffering from metastatic breast cancer; c) treating a subject suffering from refractory breast cancer; d) treating a subject suffering from AR-positive breast cancer; e) treating a subject suffering from AR-positive refractory breast cancer; f) treating a subject suffering from AR-positive metastatic breast cancer; g) treating a subject suffering from AR-positive and ER-positive breast cancer; h) treating a subject suffering from triple negative breast cancer; i) treating a subject suffering from advanced breast cancer; j) treating a subject suffering from breast cancer that has failed SERM (tamoxifen, toremifene), aromatase inhibitor, trastuzumab (Herceptin, ado-trastuzumab emtansine), pertuzumab (Perjeta), lapatinib, exemestane (Aromasin), bevacizumab (Avastin), and/or fulvestrant treatments; k) treating, preventing, suppressing or inhibiting metastasis in a subject suffering from breast cancer; l) prolonging survival of a subject with breast cancer, and/or m) prolonging the progression-free survival of a subject with breast cancer; comprising administering to the subject a therapeutically effective amount of a selective androgen receptor modulator (SARM) compound, comprising administering to the subject a therapeutically effective amount of a SARM compound of this invention. | 01-16-2014 |
20140051764 | SOLID FORMS OF SELECTIVE ANDROGEN RECEPTOR MODULATORS - The present invention relates to solid forms of (S)—N-(4-cyano-3-(trifluoromethyl)phenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide and process for producing the same. | 02-20-2014 |
20140336262 | PHARMACEUTICAL COMPOSITIONS COMPRISING NAPTHAMIDES - Disclosed herein are naphthamide and quinoline carboxamide compounds containing two bicyclic moieties, pharmaceutical compositions comprising those compounds and methods of using the compositions in the treatment of cancers mediated by cyclic-AMP (cAMP) response element binding protein (CREB). The disclosed compositions have utility in the treatment of lung, prostate and breast cancers in a human subject. | 11-13-2014 |
20140350116 | USES OF HISTONE ACETYLTRANSFERASE ACTIVATORS - The invention provides methods for enhancing histone acylation, learning, memory and/or cognition in subjects with compound (I) or compositions comprising compound (I), or a pharmaceutically acceptable salt thereof. | 11-27-2014 |
20150038587 | NOVEL CRYSTALLINE FORMS OF (1S,2R)-2-(AMINO METHYL)-N,N-DIETHYL-1-PHENYL CYCLOPROPANE CARBOXAMIDE - The present invention relates to novel crystalline forms of (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide. Processes for the preparation of this form, compositions containing the form, and methods of use thereof are also described. | 02-05-2015 |
20150148424 | STABLE DOSAGE FORMS OF LEVOMILNACIPRAN - The present invention relates to stable dosage forms of levomilnacipran and pharmaceutically acceptable salts thereof. Processes for the preparation of these dosage forms and methods of using these dosage forms are also described. | 05-28-2015 |
20150353476 | CRYSTALLINE FORM OF VSN16 - The present invention relates to a compound of formula (I) in crystalline form, wherein said compound is in the form of the free base or a pharmaceutically acceptable salt thereof, or a solvate of the free base or salt form thereof. The invention also relates to a pharmaceutical composition containing said crystalline form as an active ingredient, and use thereof in the prevention or treatment of disease. The invention further relates to a process for preparing the crystalline form. | 12-10-2015 |